system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cell Cycle, Cell Line, Tumor, Cell Proliferation, DNA Primers, Dose-Response Relationship, Drug, Drug Delivery Systems, Flow Cytometry, Humans, In Vitro Techniques, Lung Neoplasms, Octreotide, Paclitaxel, RNA, Messenger, Receptors, Somatostatin, Reverse Transcriptase Polymerase Chain Reaction.
user
Do paclitaxel-octreotide conjugates inhibit growth of human non-small cell lung cancer cells in vitro? Context: To evaluate the effects of paclitaxel-octreotide conjugates on the growth of cultured non-small cell lung cancer cells. RT-PCR was performed to detect mRNA for the subtypes of the human somatostatin receptor (SSTR) using specific primers. MTT-based cytotoxicity assay was used to evaluate the cell viability after treatment with paclitaxel and the conjugates. Cell cycle perturbations were determined using a Fluorescence-Activated Cell Sorter. Non-small cell lung cancer A549 and Calu-6 cells expressed mRNA for SSTR2 and SSTR5. Paclitaxel and the conjugates effectively inhibited the growth of A549 and Calu-6 cells in a concentration- and time-dependent manner. In SSTR-negative fibroblasts, the conjugates were less cytotoxic than paclitaxel. The conjugates and paclitaxel could induce the increase of G(2)/M phase ratio in A549 cells.
assistant
The paclitaxel-octreotide conjugates can be used as selective-targeted chemotherapeutic agents for treating non-small cell lung cancer. Final Decision: yes